zentalis_logo_large.jpg
Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary
June 27, 2022 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals to Participate in the Jefferies Healthcare Conference
June 01, 2022 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President
May 31, 2022 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock
May 18, 2022 16:01 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock
May 16, 2022 07:28 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Appoints Oncology Clinical Development Veteran Dr. Kimberly Blackwell as Chief Executive Officer
May 16, 2022 07:00 ET | ZENTALIS PHARMACEUTICALS
Dave Johnson appointed as Chairman of the Board Anthony Sun, MD, former CEO of Zentalis, to remain CEO of joint venture, Zentera Therapeutics NEW YORK and SAN DIEGO, May 16, 2022 ...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update
May 05, 2022 07:00 ET | ZENTALIS PHARMACEUTICALS
Announced initial data on ZN-c3 in combination with chemotherapy in advanced ovarian cancer and interim data on ZN-c3 in uterine serous carcinoma (USC) at AACR Received a $25 million equity...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer
April 27, 2022 07:00 ET | ZENTALIS PHARMACEUTICALS
Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells Adam Schayowitz, Ph.D., MBA, Vice...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR
April 11, 2022 16:01 ET | ZENTALIS PHARMACEUTICALS
ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts ZN-c3 demonstrated...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR
April 08, 2022 13:00 ET | ZENTALIS PHARMACEUTICALS
ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts ZN-c3 in combination...